Merola, Joe, Howard Sofen, Diamant Thaci, Carle Paul, Shinichi Imafuku, Subhashis Banerjee, and April Armstrong. “Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy Analysis by Baseline Disease Characteristics From the Phase 3 POETYK PSO-1 and PSO-2 Trials”. SKIN The Journal of Cutaneous Medicine 5, no. 6 (November 5, 2021): s36. Accessed August 13, 2022.